Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7738368 | 1.00 | LMNA (0.48) | LMNACYP2D6MAPTNFKB1CYP1A2 | |
| SCHEMBL25272156 | 0.93 | CYP2D6 (0.48) | LMNACYP2D6MAPTNFKB1CYP1A2 | |
| SCHEMBL25272157 | 0.93 | CYP2D6 (0.48) | LMNACYP2D6MAPTNFKB1CYP1A2 | |
| SCHEMBL30343570 | 0.86 | — | — | |
| SCHEMBL11656320 | 0.77 | USP2 (0.33) | — | |
| SCHEMBL379236 | 0.76 | LMNA (0.47) | LMNACYP2D6MAPTNFKB1CYP1A2 | |
| SCHEMBL1712974 | 0.76 | LMNA (0.47) | LMNACYP2D6MAPTNFKB1CYP1A2 | |
| SCHEMBL9644802 | 0.75 | TSHR (0.52) | LMNATSHR | |
| SCHEMBL11653010 | 0.75 | USP2 (0.37) | — | |
| SCHEMBL10415139 | 0.72 | HMGCR (0.59) | LMNACYP2D6MAPTNFKB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130316989-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | RESOLVYX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | SCHWARTZ C ERIC | 2011-10-06 | — | — | US | disclosed |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010039531-A1 | THERAPEUTIC COMPOUNDS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-0866791-B1 | DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL | ARPIDA AG (CH) | 2002-01-30 | — | — | EP | disclosed |
| EP-1149834-A1 | Diaminopyrimidines, pharmaceutical compositions containing them and their use as antibacterial | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| EP-0866791-A1 | DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-30 | — | — | EP | disclosed |
| US-5773446-A | BACTERICIDES; CONTROLLING INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997020839-A1 | DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130316989-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | ALOX15B, ALOX12, ALOX15 | LMNA 623/4885CYP2D6 1110/4885MAPT 4177/4885 |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | ALOX5, ALOX15B, ALOX12 | LMNA 1445/4885CYP2D6 773/4885MAPT 3683/4885 |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | ALOX15B, ALOX12, ALOX15 | LMNA 623/4885CYP2D6 1110/4885MAPT 4177/4885 |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | ALOX5, ALOX15B, ALOX12 | LMNA 327/4885CYP2D6 1848/4885MAPT 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.